Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis

Clicks: 2
ID: 317760
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #323 of 333 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Pathological complete response (pCR) and circulating tumor DNA (ctDNA) clearance are increasingly used as intermediate endpoints in neoadjuvant and perioperative immunotherapy (IO) trials. However, whether complete pathological and molecular responders share comparable residual risk across tumor types remains uncertain. METHODS: We performed a post-hoc pan-tumor analysis using reconstructed individual patient data from published Kaplan-Meier curves of phase II/III trials. All included trials contained a neoadjuvant immunotherapy component; trials that additionally incorporated postoperative adjuvant immunotherapy were classified as perioperative. We evaluated associations of pCR and ctDNA clearance, defined as conversion from baseline ctDNA positivity to undetectable ctDNA after neoadjuvant therapy, with event-free survival (EFS) and tested whether these biomarkers modified the association between treatment timing (neoadjuvant-only versus perioperative) and EFS. FINDINGS: We reconstructed survival data for 1,867 patients achieving pCR and 352 patients achieving ctDNA clearance across 8 tumor types. Among patients with pCR, 3-year EFS varied substantially by tumor type (from 78.6% to 100%). In tumor types where such a comparison was possible, postoperative adjuvant IO did not improve EFS among patients achieving pCR. In contrast, ctDNA clearance showed heterogeneous prognostic dynamics. In within-tumor analyses restricted to trials reporting both endpoints, pCR was associated with superior EFS. CONCLUSION: pCR remains the most reproducible prognostic indicator across tumor types following neoadjuvant or perioperative IO. In cross-trial comparisons, no EFS benefit from postoperative adjuvant IO was observed among patients with pCR. ctDNA clearance showed substantial variability across tumors, likely reflecting both biological heterogeneity in tumor shedding and inter-trial assay differences.
Reference Key
openalex_W7165366489 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yago Garitaonaindía, Sonja Witteveen, Edoardo Dionisio, Anne Weiss, Eva Ellebaek, Christian Rolfo, Mariano Provencio, Christian Blank, Marco Donia
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag197
URL
https://doi.org/10.1093/jnci/djag197
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.